Healthcare Jun 24, 2022 10:46 AM (GMT+8) · EqualOcean
On June 23, Huadong pharmaceutical announced that it had reached a strategic cooperation with Gulf pharmaceutical industries PJSC (Julphar), a well-known enterprise in the Middle East. Julphar will obtain the development, production and commercialization rights and interests of the two indications of liraglutide injection diabetes and weight loss in 17 countries in the Middle East and North Africa, such as the United Arab Emirates, Saudi Arabia, Egypt, Kuwait, Oman and Bahrain. According to the agreement, Huadong pharmaceutical will obtain the authorized down payment, development and registration milestone payment, and the agreed proportion of net sales share. Huadong pharmaceutical said that after the completion of this transaction, liraglutide injection will become the second overseas authorized product after ttp273. In addition, Huadong pharmaceutical liraglutide injection (diabetes indication) is the first domestic drug to submit a listing application. At present, the drug registration verification has been completed and it is expected to be the first to be approved for listing in China by the end of 2022.

This text is a result of machine translation.